Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free
Can-Fite BioPharma AMEX CANF
$1.94 -0.03 -1.55%
Today share price
Israel
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 20 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

8.79M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
4.54M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.51
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
4.53M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-11.82 %
Upcoming events Can-Fite BioPharma All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart Can-Fite BioPharma

Stock analysis Can-Fite BioPharma

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-1.18 -0.85
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
1.41 2.04
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
- -0.66
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
- 0.24
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-119.69 -87.14

Price change Can-Fite BioPharma per year

1.48$ 3.07$
Min Max

Summary analysis Can-Fite BioPharma

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Can-Fite BioPharma

Revenue and net income Can-Fite BioPharma

All parameters
Stock news Can-Fite BioPharma All news
21 November 2023 в 18:24

Can-Fite BioPharma ADRs Rise 13% on Patient Outcome on Liver Cancer Treatment

21 November 2023 в 18:24

Can-Fite BioPharma ADRs Rise 13% on Patient Outcome on Liver Cancer Treatment

1 May 2023 в 16:00

Can-Fite Biopharma upgraded to buy from neutral at Dawson James

25 January 2023 в 01:40

ADRs End Lower; AstraZeneca, Can-Fite BioPharma Trade Actively

25 January 2023 в 01:35

ADRs End Lower; AstraZeneca, Can-Fite BioPharma Trade Actively

11 January 2023 в 19:11

Can-Fite BioPharma Shares Drop 9% After Direct Offering, Private Placement

11 January 2023 в 19:05

Can-Fite BioPharma Shares Drop 9% After Direct Offering, Private Placement

18 August 2022 в 01:01

ADRs End Lower; Can-Fite BioPharma, Kyocera Trade Actively

18 August 2022 в 01:01

ADRs End Lower; Can-Fite BioPharma, Kyocera Trade Actively

12 July 2022 в 00:15

ADRs End Lower; BP, Can-Fite BioPharma Trade Actively

12 July 2022 в 00:15

ADRs End Lower; BP, Can-Fite BioPharma Trade Actively

30 June 2022 в 00:25

ADRs End Lower; BioLineRx, Can-Fite BioPharma Trade Actively

30 June 2022 в 00:25

ADRs End Lower; BioLineRx, Can-Fite BioPharma Trade Actively

29 June 2022 в 14:40

Can-Fite BioPharma Shares Jump Premarket on Piclidenoson Study Results >CANF

29 June 2022 в 14:36

Can-Fite BioPharma Shares Jump Premarket on Piclidenoson Study Results >CANF

30 December 2021 в 00:36

ADRs End Mostly Lower; Can-Fite Biopharma Up on Patent Applications

30 December 2021 в 00:35

ADRs End Mostly Lower; Can-Fite Biopharma Up on Patent Applications

21 December 2021 в 18:00

Can-Fite BioPharma Shares Drop 10% After Warrants Agreement

21 December 2021 в 18:00

Can-Fite BioPharma Shares Drop 10% After Warrants Agreement

20 December 2021 в 17:40

Can-Fite BioPharma Shares Jump 80% on Complete Response for Namodenoson

About company Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel.
Address:
10 Bareket Street, Petah Tikva, Israel, 4951778
Company name: Can-Fite BioPharma
Issuer ticker: CANF
ISIN: US13471N2018
Country: Israel
Exchange: AMEX
Currency: $
IPO date: 2012-11-06
Sector: Healthcare
Industry: Biotechnology
Site: https://www.canfite.com

On which stock exchange are Can-Fite BioPharma (CANF) stocks traded?

Can-Fite BioPharma (CANF) stocks are traded on AMEX.

What is the ticker of Can-Fite BioPharma stocks (CANF)?

The stock ticker of Can-Fite BioPharma’s stocks or in other words, the code is CANF. The stocks are currently listed on the AMEX exchange.

In which sector and industry does Can-Fite BioPharma (CANF) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Can-Fite BioPharma (CANF) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Can-Fite BioPharma (CANF) stocks traded?

Can-Fite BioPharma (CANF) stocks are traded on the AMEX exchange in dollars.

What is the price of Can-Fite BioPharma (CANF) stocks today?

The current price of Can-Fite BioPharma stocks on 25.04.2024 is 1.94 dollars. per share.

What is the dynamics of Can-Fite BioPharma (CANF) stocks from the beginning of the year?

Can-Fite BioPharma (CANF) quotes have increased by -6.28% from the beginning of the year up to 1.94 dollars. per 1 stocks.

How much did Can-Fite BioPharma (CANF) stocks increase in апреле 2024?

This month Can-Fite BioPharma (CANF) quotes have increased by -16.02% to 1.94 dollars. per share.

How much are Can-Fite BioPharma (CANF) stocks worth?

Today, on October, 25.04.2024 Can-Fite BioPharma’s (CANF) stocks cost 1.94 dollars..

What is the market capitalization of Can-Fite BioPharma (CANF)?

Capitalization is the market value of Can-Fite BioPharma (CANF) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 25.04.2024, the market capitalization of Can-Fite BioPharma (CANF) is estimated at about 8793615 dollars.